AWARD OUTCOME
What happened
Velindre University NHS Trust has announced a pending direct award to Swedish Orphan Biovitrum (SOBI) for Altuvoct (efanesoctocog alfa), a pharmaceutical product. The notice says the medicine is NICE approved and is not available through the NHS England Bleeding Disorders Framework; the stated purpose is access for Welsh patients while a supplier contract is negotiated with NHS England.
Published outcomeAward 1 is pending, with a scheduled future signature date of 27 October 2026. The published record does not evidence a signed or active contract.
Market significanceThis is a GBP 270,000 net direct award for a specialised pharmaceutical product, above threshold, with a published gross value of GBP 324,000.
AWARDED SUPPLIERS AND LOTS
1 supplier record analysed
Swedish Orphan Biovitrum (SOBI)
98% confidenceAward 1 · Lots 1 · 270000 GBP · pending
View supporting evidence
Award 1 identifies Swedish Orphan Biovitrum (SOBI) as supplier and gives a GBP 270,000 value. This is the single published award value, not evidence of a signed contract.
LIFECYCLE
Award or contract stage
Published award status
99% confidencePending
View supporting evidence
Award 1 has status "pending" in the contract award notice data.
Tender/lot status
97% confidenceComplete
View supporting evidence
Tender and lot 1 are each marked "complete".
Scheduled future signature date
98% confidence27 October 2026
View supporting evidence
Award milestone type "futureSignatureDate" is scheduled for 2026-10-27.
Contract conclusion
99% confidenceNot evidenced
View supporting evidence
The award is pending and the source provides only a scheduled future signature milestone.
VALUES
Published values explained
Award value (net)
99% confidenceGBP 270,000
View supporting evidence
Award 1 value.amount is 270000 GBP.
Award value (gross)
99% confidenceGBP 324,000
View supporting evidence
Award 1 value.amountGross is 324000 GBP.
Value allocation
94% confidenceAllocated to the single published award for lot 1
View supporting evidence
Award 1 names one supplier and relates to lot 1.
TIMELINE
Procurement timeline
Transparency notice published
98% confidence30 September 2026
View supporting evidence
Release history records transparency notice 092163-2026 at 2026-09-30T09:45:44+01:00.
Contract award notice published
99% confidence14 October 2026
View supporting evidence
Award document 096904-2026 was published at 2026-10-14T11:29:52+01:00.
Award decision date
98% confidence14 October 2026
View supporting evidence
Award 1 date is 2026-10-14.
Standstill end
98% confidence23 October 2026
View supporting evidence
Award 1 standstill period ends 2026-10-23T23:59:59+01:00.
Published contract period
98% confidence27 October 2026 to 17 August 2028
View supporting evidence
Award 1 contractPeriod lists these start and end dates.
SCOPE
What was awarded
Requirement
99% confidenceProvision of Altuvoct (efanesoctocog alfa) recombinant FVII
View supporting evidence
This is the published process and award title.
Category
99% confidenceGoods — pharmaceutical products
View supporting evidence
Award 1 main procurement category is goods; item CPV 33600000 is Pharmaceutical products.
Lot
96% confidenceLot 1
View supporting evidence
Award 1 relates to lot 1. No lot title or description was published.
Delivery geography
92% confidenceUnited Kingdom
View supporting evidence
The award item delivery address is region UK, country GB.
Stated access rationale
96% confidenceAccess for Welsh patients while the supplier and NHS England negotiate a contract
View supporting evidence
The procurement description states this rationale.
PROCEDURE
Procedure and competition
Procedure
99% confidenceDirect award
View supporting evidence
The process procurementMethod and procurementMethodDetails are direct and Direct award.
Regulatory basis
98% confidenceProcurement Act 2023 (2023 c.54)
View supporting evidence
Tender legalBasis identifies UKPGA 2023/54.
Above-threshold status
99% confidenceYes
View supporting evidence
Award 1 is marked aboveThreshold: true.
Competition information
99% confidenceNot supplied in the published notice
View supporting evidence
No bid count, competing suppliers, evaluation results or scoring are provided.
Transparency notice issue
98% confidenceThe buyer states the transparency notice was not published at the required process stage due to a procedural oversight; corrective action was taken.
View supporting evidence
This is stated in the procurement description.
CONTRACT TERMS
Published contract terms
Published contract period
98% confidence27 October 2026 to 17 August 2028
View supporting evidence
Award 1 contractPeriod provides the dates.
Signature status
99% confidenceNot evidenced; signature is scheduled
View supporting evidence
The record has a pending award and a futureSignatureDate milestone of 27 October 2026.
Extension or renewal terms
99% confidenceNot supplied in the published notice
View supporting evidence
No extension or option terms are provided.
COMMERCIAL VIEW
Commercial observations
Procurement route context
96% confidenceThe buyer states that Altuvoct was not available under the NHS England Bleeding Disorders Framework at the time of the notice.
View supporting evidence
This is stated in the procurement description.
Market access context
96% confidenceThe notice describes the arrangement as an interim route for Welsh patient access while a supplier contract is negotiated with NHS England.
View supporting evidence
This is stated in the procurement description.
Award maturity
98% confidenceSuppliers should treat the award as pre-signature because it remains pending and standstill had a published end date after the award notice.
View supporting evidence
Award status is pending; standstill ends 23 October 2026; future signature is scheduled for 27 October 2026.
DATA QUALITY
Gaps and source limitations
Pending award versus contract status
99% confidenceThe published award is pending, not evidence of a signed or active contract.
View supporting evidence
Award 1 status is pending and a future signature milestone is scheduled.
Transparency timing
98% confidenceThe buyer reports that the transparency notice was not issued at the required process stage.
View supporting evidence
Procurement description attributes this to a procedural oversight and describes corrective action.
Supplier identity
99% confidenceNo verified legal company name or company number was supplied; the published supplier name is used as unverified source identity.
View supporting evidence
verified_company_name and verified_company_number are null; verification status is not_applicable.
Lot detail
99% confidenceLot 1 has no published title, description or individual lot value.
View supporting evidence
Lot record fields are null for title, description and value.
Information not supplied in the published notice
99% confidenceNo bid count, evaluation detail, pricing breakdown, extension terms or detailed delivery location was published.
View supporting evidence
These fields are absent from the supplied notice data.
SOURCE DATA LIMITATIONS
Information not supplied in the published notice
- The award remains pending; the record does not demonstrate that a contract has been signed, started or is active.
- The buyer reports a procedural oversight in the timing of the transparency notice; this analysis does not determine legal effect.
- No verified legal company name or company number was supplied for Swedish Orphan Biovitrum (SOBI); the name is presented as the unverified published supplier identity.
- Lot 1 has no published title, description or separate value.
- Information not supplied in the published notice includes bid numbers, evaluation results, pricing detail, extension options and detailed delivery arrangements.
MARKET THEMES
Relevant award themes
Velindre University NHS TrustSwedish Orphan Biovitrum (SOBI)Altuvoctefanesoctocog alfapharmaceutical productsdirect awardProcurement Act 2023
COMMON QUESTIONS
About this award
Who is the published supplier for the Altuvoct award?
The published supplier is Swedish Orphan Biovitrum (SOBI). No verified legal company name was supplied in the record.
Has the Altuvoct contract been signed?
The supplied record does not evidence signature. Award 1 is pending and lists 27 October 2026 as a scheduled future signature date.
What is the published award value?
The award value is GBP 270,000 net, with a published gross amount of GBP 324,000.
Why was a direct award used?
The buyer states that the NICE-approved medicine was not available through the NHS England Bleeding Disorders Framework and was needed for Welsh patient access while an NHS England contract was being negotiated.
ProcuraAxis award analysis supplements, but does not replace, the official award notice, contract data or procurement documents. “Awarded” does not by itself prove that a contract has been signed.